Search research articles
Contact Us
Filters
Showing results (931-940 of 1,095) with videos related to
Page
of 110
Sort By:
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
Journal of Hepatology
|
January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
George V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.
Journal of Viral Hepatitis
|
March 3, 2026
Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis
Christos Thomadakis, Ilias Gountas, Konstantinos Gountas, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Alimentary Pharmacology & Therapeutics
|
September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver Disease
Lesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The Journal of Urology
|
July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma
Matteo Santoni, Alessandro Conti, Camillo Porta, et al.
Journal of Viral Hepatitis
|
December 10, 2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
S Alonso, M Riveiro-Barciela, I Fernandez, et al.
Immunotherapy
|
January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Page
of 110
Search research articles
Search
Showing results (931-940 of 1,095) with videos related to
Sort By:
Page
of 110
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
Journal of Hepatology
|
January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
George V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.
Journal of Viral Hepatitis
|
March 3, 2026
Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis
Christos Thomadakis, Ilias Gountas, Konstantinos Gountas, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Alimentary Pharmacology & Therapeutics
|
September 9, 2025
Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver Disease
Lesley A Patmore, Ivana Carey, Jordan J Feld, et al.
The Journal of Urology
|
July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma
Matteo Santoni, Alessandro Conti, Camillo Porta, et al.
Journal of Viral Hepatitis
|
December 10, 2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
S Alonso, M Riveiro-Barciela, I Fernandez, et al.
Immunotherapy
|
January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Page
of 110